Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Curr Atheroscler Rep. 2008 Feb;10(1):88-95.

Liver X receptors as therapeutic targets in metabolism and atherosclerosis.

Author information

  • 1Division of Endocrinology and Molecular Medicine, Department of Internal Medicine, University of Kentucky College of Medicine, Wethington Health Sciences Building, Room 575, 900 South Limestone Street, Lexington, KY 40536, USA.

Abstract

The liver X receptors (LXRs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. Since their initial identification more than a decade ago, LXRs have been characterized as key transcriptional regulators of lipid and carbohydrate homeostasis. LXRs are activated by the intracellular accumulation of cholesterol derivatives to stimulate cholesterol efflux and reverse cholesterol transport and excretion into the bile. Glucose functions as an LXR ligand in carbohydrate metabolism, and receptor agonism suppresses hepatic gluconeogenesis and improves insulin sensitivity. In addition to these beneficial metabolic effects, LXR ligands suppress inflammatory and proliferative responses of vascular cells and prevent the development of atherosclerosis and its complications. In this review, we summarize the important roles of LXRs in metabolism and vascular biology and discuss their implications as potential molecular drug targets for the treatment of cardiovascular diseases.

PMID:
18366990
[PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk